ArticleNature communications2014
Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- Retinal pathological features and proteome signatures of Alzheimer's disease.Acta neuropathologica · 2023Article
- A Kinetic Map of the Influence of Biomimetic Lipid Model Membranes on AβACS chemical neuroscience · 2023Article
- Reduced levels of NGF shift astrocytes toward a neurotoxic phenotype.Frontiers in cell and developmental biology · 2023Article
- Stress-induced protein disaggregation in the endoplasmic reticulum catalysed by BiP.Nature communications · 2022Article
- The Diagnostic Potential of Amyloidogenic Proteins.International journal of molecular sciences · 2021Review
- Selection and Modelling of a New Single-Domain Intrabody Against TDP-43.Frontiers in molecular biosciences · 2021Article
- Article
- Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
- Rational design of a conformation-specific antibody for the quantification of Aβ oligomers.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Advances in protein misfolding, amyloidosis and its correlation with human diseases.3 Biotech · 2020Review
- Impaired adult neurogenesis is an early event in Alzheimer's disease neurodegeneration, mediated by intracellular Aβ oligomers.Cell death and differentiation · 2020Article
- Alzheimer's Retinopathy: Seeing Disease in the Eyes.Frontiers in neuroscience · 2020Review
- Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis.Frontiers in cellular neuroscience · 2020Review
- Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology.The Journal of clinical investigation · 2019Article
- Article
- Current Concepts of Antigen Cross-Presentation.Frontiers in immunology · 2018Review
- A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers.Journal of neurochemistry · 2017Article
- Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.JCI insight · 2017Article
- Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.Cellular and molecular life sciences : CMLS · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aβ oligomers (AβOs) are crucially involved in Alzheimer's Disease (AD). However, the lack of selective approaches for targeting these polymorphic Aβ assemblies represents a major hurdle in understanding their biosynthesis, traffic and actions in living cells. Here, we established a subcellularly localized conformational-selective interference (CSI) approach, based on the expression of a recombinant antibody fragment against AβOs in the endoplasmic reticulum (ER). By CSI, we can control extra- and intracellular pools of AβOs produced in an AD-relevant cell model, without interfering with the maturation and processing of the Aβ precursor protein. The anti-AβOs intrabody selectively intercepts critical AβO conformers in the ER, modulating their assembly and controlling their actions in pathways of cellular homeostasis and synaptic signalling. Our results demonstrate that intracellular Aβ undergoes pathological oligomerization through critical conformations formed inside the ER. This establishes intracellular AβOs as key targets for AD treatment and presents CSI as a potential targeting strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.